BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/6/2021 2:31:17 AM | Browse: 469 | Download: 713
 |
Received |
|
2021-02-26 19:22 |
|
Peer-Review Started |
|
2021-02-26 19:26 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-04-05 16:32 |
|
Revised |
|
2021-04-13 04:04 |
|
Second Decision |
|
2021-06-02 11:18 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-06-02 13:07 |
|
Articles in Press |
|
2021-06-02 13:07 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-06-30 01:55 |
|
Publish the Manuscript Online |
|
2021-07-06 02:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Approach to medical therapy in perianal Crohn’s disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abhinav Vasudevan, David H Bruining, Edward V Loftus Jr, William Faubion, Eric C Ehman and Laura Raffals |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abhinav Vasudevan, BMed, FRACP, N/A, PhD, Doctor, Doctor, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States. vasudevan.abhinav@mayo.edu |
| Key Words |
Fistula; Biologics; Inflammatory bowel disease; Surgery; Stem cells; Infliximab; Ustekinumab |
| Core Tip |
Early commencement of anti-tumor necrosis factor (anti-TNF) therapy in perianal Crohn’s disease is preferred over delaying treatment, although perianal sepsis should be treated first. Symptomatic remission remains the treatment goal, with radiographic healing an evolving target. Concomitant antibiotic therapy while initiating anti-TNF therapy is efficacious. Therapeutic drug monitoring and dose adjustment of anti-TNF therapy, targeting a higher trough level than what is routinely used for luminal disease, may improve treatment response. Ustekinumab may be efficacious in anti-TNF refractory individuals, although more studies are needed. Mesenchymal stem cell injection can be used in individuals who are refractory to anti-TNF therapy. |
| Publish Date |
2021-07-06 02:31 |
| Citation |
Vasudevan A, Bruining DH, Loftus EV Jr, Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn’s disease. World J Gastroenterol 2021; 27(25): 3693-3704 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i25/3693.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i25.3693 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
